HRT extended use not cardioprotective
Executive Summary
Continued use of hormone replacement therapy by postmenopausal women with coronary heart disease does not offer cardioprotective benefit, Wyeth-sponsored Heart and Estrogen/Progestin Replacement Study II data published in June 3 Journal of the American Medical Association show. HERS II found no reduced risk of CHD events for 1,380 women taking .625 mg of conjugated estrogens/2.5 mg of medroxyprogesterone daily during 2.7-year open-label study. HERS II is a follow-up to the 4.1 year HERS trial, which suggested a decreased risk for the third through fifth years of hormone therapy (1"The Pink Sheet" Aug. 24, 1998, p. 11)...
You may also be interested in...
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention
Wyeth Premarin/Prempro Cardioprotection Claim On Hold Until 2005
Wyeth-Ayerst's pursuit of a cardioprotection claim for conjugated estrogens is likely delayed until 2005-2007 following the negative outcome of the Heart and Estrogen/Progestin Replacement Study.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: